TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preoperative Methylprednisolone to Patients Suspected of Appendicitis Undergoing Laparoscopy
Brief Summary: To test whether 125 mg preoperative methylprednisolone intravenously can reduce postoperative pain after laparoscopy for suspected appendicitis and to test whether preoperative methylprednisolone can reduce postoperative fatigue, increase quality of sleep, reduce nausea or vomiting, reduce duration of convalescence and increase overall quality of recovery after laparoscopy for suspected appendicitis.


Options:
A: Arm Label: Ramosetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramosetron | Intervention Type: DRUG; Name: Ramosetron; Assigned to Arm(s): Ramosetron
B: Arm Label: Methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Methylprednisolone | Intervention Type: DRUG; Name: 0.9% Saline; Assigned to Arm(s): Placebo
C: Arm Label: A, 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A, 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethason Helvepharm ® | Intervention Type: DRUG; Name: Dexamethason Helvepharm ®; Assigned to Arm(s): A, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A, 1
D: Arm Label: Adductor Canal block; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adductor canal block, Drug: Bupivacaine, Drug: Fentanyl, Drug: Ropivacaine 0.5% Injectable Solution | Arm Label: Adductor canal block with dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adductor canal block with dexamethasone, Drug: Bupivacaine, Drug: Fentanyl, Drug: Ropivacaine 0.5% Injectable Solution, Drug: Dexamethasone | Arm Label: Adductor canal catheter; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adductor canal catheter, Drug: Bupivacaine, Drug: Fentanyl, Drug: Ropivacaine 0.5% Injectable Solution | Intervention Type: DRUG; Name: Adductor canal block; Assigned to Arm(s): Adductor Canal block | Intervention Type: DRUG; Name: Adductor canal block with dexamethasone; Assigned to Arm(s): Adductor canal block with dexamethasone | Intervention Type: DRUG; Name: Adductor canal catheter; Assigned to Arm(s): Adductor canal catheter | Intervention Type: DRUG; Name: Bupivacaine; Assigned to Arm(s): Adductor Canal block, Adductor canal block with dexamethasone, Adductor canal catheter | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): Adductor Canal block, Adductor canal block with dexamethasone, Adductor canal catheter | Intervention Type: DRUG; Name: Ropivacaine 0.5% Injectable Solution; Assigned to Arm(s): Adductor Canal block, Adductor canal block with dexamethasone, Adductor canal catheter | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Adductor canal block with dexamethasone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adapting and Implementing the Blended Collaborative Care Model in CBOCs
Brief Summary: Integrating mental health treatments into the primary care delivered at Community Based Outpatient Clinics(CBOCs) that are geographically accessible to rural Veterans is a major priority for the Department of Veterans Affairs. However, there is no scientific evidence that integrating mental health and primary care is clinically effective at smaller CBOCs that have limited mental health staffing. The goal of this proposed project is to implement a "blended" combination of integrated care models that have been adapted for smaller CBOCs using telemedicine technologies, and evaluate the acceptability and effectiveness of the blended, telemedicine-based, integrated care model. If clinical outcomes are improved compared to usual care, findings will be used to justify and facilitate the implementation of this telemedicine-based integrated care model at smaller CBOCs in order to increase rural Veterans' access to effective mental health treatments.


Options:
A: Arm Label: Experimental; Type: N/A; Interventions: Other: CAPRI | Arm Label: Control; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: CAPRI; Assigned to Arm(s): Experimental
B: Arm Label: Pre-Implementation Cohort; Type: N/A; Interventions: Other: Usual Care | Arm Label: Post-Implementation Cohort; Type: N/A; Interventions: Other: Blended Telemedicine-Based Integrated Care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Pre-Implementation Cohort | Intervention Type: OTHER; Name: Blended Telemedicine-Based Integrated Care; Assigned to Arm(s): Post-Implementation Cohort
C: Arm Label: Traditional follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine follow-up care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Telemedicine follow-up care | Intervention Type: PROCEDURE; Name: Telemedicine follow-up care; Assigned to Arm(s): Telemedicine follow-up care
D: Arm Label: Rural Veterans; Type: N/A; Interventions: Other: Direct to patient facing mobile apps introduction | Arm Label: Nonrural Veterans; Type: N/A; Interventions: Other: Direct to patient facing mobile apps introduction | Intervention Type: OTHER; Name: Direct to patient facing mobile apps introduction; Assigned to Arm(s): Nonrural Veterans, Rural Veterans

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Palliative Care to Improve Quality of Life in CHF and COPD
Brief Summary: Chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD), and interstitial lung disease (i.e., pulmonary fibrosis) are common serious illnesses. Despite disease-specific medical care, people with these illnesses often left with poor quality of life (i.e., burdensome symptoms, impaired function). Furthermore, while these illnesses are leading causes of hospitalization and mortality, few people with these illnesses engage in advance care planning, the process of considering and communicating healthcare values and goals. The investigators are conducting a randomized clinical trial to study a symptom management, psychosocial care and advance care planning intervention to improve quality of life. The study is important because it aims to improve quality of life and provision of care according to peoples' goals and preferences in common, burdensome illnesses. Furthermore, this study will generate information that supports the broader dissemination and implementation of the intervention and informs the development of future palliative care and team-based interventions in the VA.


Options:
A: Intervention Type: BEHAVIORAL; Name: Patient-Centered Advance Care Planning; Assigned to Arm(s): N/A
B: Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention (ACP) arm; Type: EXPERIMENTAL; Interventions: Behavioral: ACP | Intervention Type: BEHAVIORAL; Name: ACP; Assigned to Arm(s): Intervention (ACP) arm
C: Arm Label: Goc Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: goals of care | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: goals of care; Assigned to Arm(s): Goc Intervention
D: Arm Label: ADAPT Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ADAPT Intervention | Arm Label: Enhanced usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ADAPT Intervention; Assigned to Arm(s): ADAPT Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wisconsin Tobacco Quit Line Centers for Medicaid Services Striving To Quit Evaluation Project
Brief Summary: The study is designed to test the hypotheses that financial incentives can increase both participation in smoking cessation treatment and resulting cessation rates, when they are offered to BadgerCare Plus (Medicaid) smokers as part of their health care.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling from WTQL | Arm Label: Incentive; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling from WTQL, Other: Financial incentive to participate | Intervention Type: BEHAVIORAL; Name: Counseling from WTQL; Assigned to Arm(s): Control, Incentive | Intervention Type: OTHER; Name: Financial incentive to participate; Assigned to Arm(s): Incentive
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Individual Rewards; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Rewards | Arm Label: Fixed Deposits; Type: EXPERIMENTAL; Interventions: Behavioral: Fixed Deposits | Arm Label: Competitive Deposits (Pari-Mutuel); Type: EXPERIMENTAL; Interventions: Behavioral: Competitive Deposits (Pari-Mutuel) | Arm Label: Collaborative Rewards; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Rewards | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care | Intervention Type: BEHAVIORAL; Name: Individual Rewards; Assigned to Arm(s): Individual Rewards | Intervention Type: BEHAVIORAL; Name: Fixed Deposits; Assigned to Arm(s): Fixed Deposits | Intervention Type: BEHAVIORAL; Name: Competitive Deposits (Pari-Mutuel); Assigned to Arm(s): Competitive Deposits (Pari-Mutuel) | Intervention Type: BEHAVIORAL; Name: Collaborative Rewards; Assigned to Arm(s): Collaborative Rewards
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Contingent reinforcement plus placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: non-contingent reinforcement plus bupropion | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Non-contingent reinforcement plus placebo | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Contingent reinforcement plus placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: non-contingent reinforcement plus bupropion; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Non-contingent reinforcement plus placebo; Assigned to Arm(s): 4
D: Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma
Brief Summary: This multi-center randomized controlled phase II trial will investigate the impact of stereotactic fractionated radiotherapy to the resection cavity of complete resected recurrent glioblastoma on progression free survival. As secondary endpoints, overall survival, safety and toxicity as well as early response criteria on MRI, quality of life and neurocognitive function will be assessed. Chemotherapy will not be part of the protocol, however, additional treatment will be possible upon investigators best choice.


Options:
A: Arm Label: Arm A: SRT to the resection cavity; Type: EXPERIMENTAL; Interventions: Radiation: SRT to the resection cavity | Arm Label: Arm B: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: RADIATION; Name: SRT to the resection cavity; Assigned to Arm(s): Arm A: SRT to the resection cavity
B: Arm Label: ADV-TK/GCV; Type: EXPERIMENTAL; Interventions: Biological: ADV-TK/GCV | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery, Drug: systemic chemotherapy | Intervention Type: BIOLOGICAL; Name: ADV-TK/GCV; Assigned to Arm(s): ADV-TK/GCV | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Control group | Intervention Type: DRUG; Name: systemic chemotherapy; Assigned to Arm(s): Control group
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alkylating Agents | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Disulfiram, Dietary Supplement: Copper, Drug: Alkylating Agents | Intervention Type: DRUG; Name: Disulfiram; Assigned to Arm(s): Experimental | Intervention Type: DIETARY_SUPPLEMENT; Name: Copper; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Alkylating Agents; Assigned to Arm(s): Control, Experimental
D: Arm Label: Cediranib 30mg; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Arm Label: Cediranib 20mg + lomustine; Type: OTHER; Interventions: Drug: Cediranib, Drug: Lomustine Chemotherapy | Arm Label: Lomustine and Placebo Cediranib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine Chemotherapy, Drug: Placebo Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 30mg | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 20mg + lomustine | Intervention Type: DRUG; Name: Lomustine Chemotherapy; Assigned to Arm(s): Cediranib 20mg + lomustine, Lomustine and Placebo Cediranib | Intervention Type: DRUG; Name: Placebo Cediranib; Assigned to Arm(s): Lomustine and Placebo Cediranib

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transversus Abdominis Plane Versus Quadratus Lumborum Block for Pediatrics
Brief Summary: The purpose of this research study is to find the best way to decrease pain in children whom have had low abdominal surgery. Investigators will perform two technique of trunk block; Transversus abdominis plane or Quadratus lumborum block .The method used is often chosen by which one the doctor has more experience using. The Investigator plans to find out if one of the methods is more effective and/or safer than the other method.

The results of this study will help learn how to best control pain in children having surgery low abdominal surgery.


Options:
A: Arm Label: Quadratus Lumborum Block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Quadratus Lumborum Block | Arm Label: Transversus abdominis plane block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transversus Abdominis Plane Block | Intervention Type: PROCEDURE; Name: Quadratus Lumborum Block; Assigned to Arm(s): Quadratus Lumborum Block | Intervention Type: PROCEDURE; Name: Transversus Abdominis Plane Block; Assigned to Arm(s): Transversus abdominis plane block
B: Arm Label: Transversus Abdominis Plane Block; Type: EXPERIMENTAL; Interventions: Procedure: Transversus Abdominis Plane Block | Arm Label: Caudal Epidural Block; Type: EXPERIMENTAL; Interventions: Procedure: Caudal Epidural | Intervention Type: PROCEDURE; Name: Caudal Epidural; Assigned to Arm(s): Caudal Epidural Block | Intervention Type: PROCEDURE; Name: Transversus Abdominis Plane Block; Assigned to Arm(s): Transversus Abdominis Plane Block
C: Arm Label: Regional block; Type: EXPERIMENTAL; Interventions: Procedure: bilateral ultrasound-guided rectus sheath block | Arm Label: Wound infiltration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wound infiltration | Intervention Type: PROCEDURE; Name: bilateral ultrasound-guided rectus sheath block; Assigned to Arm(s): Regional block | Intervention Type: PROCEDURE; Name: Wound infiltration; Assigned to Arm(s): Wound infiltration
D: Arm Label: Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levobupivacaine, Drug: Saline | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Levobupivacaine, Drug: Saline | Intervention Type: DRUG; Name: Levobupivacaine; Assigned to Arm(s): Control group, Treatment | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Control group, Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The prevention of postnatal growth failure in very low birth weight (VLBW) preterm infants is of utmost importance. Standard fortification is the most commonly used supplementation practice but it does not consider the native variability of human milk. Data on efficacy and safety of prolonged target fortification are scarce. The investigators performed a prospective interventional study in VLBW preterm infants, exclusively fed with human milk, to test efficacy and metabolic safety of target fortification in these preterm infants.


Options:
A: Arm Label: Experimental Human Milk Fortifier; Type: EXPERIMENTAL; Interventions: Other: Experimental human milk fortifier | Arm Label: Control Human Milk Fortifier; Type: ACTIVE_COMPARATOR; Interventions: Other: Control human milk fortifier | Intervention Type: OTHER; Name: Experimental human milk fortifier; Assigned to Arm(s): Experimental Human Milk Fortifier | Intervention Type: OTHER; Name: Control human milk fortifier; Assigned to Arm(s): Control Human Milk Fortifier
B: Arm Label: Standard Protein Group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard fortification | Arm Label: Enhanced Protein Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein supplementation, Dietary Supplement: Standard fortification | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein supplementation; Assigned to Arm(s): Enhanced Protein Group | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard fortification; Assigned to Arm(s): Enhanced Protein Group, Standard Protein Group
C: Arm Label: High Dose Protein (Individualized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Individualized) | Arm Label: High Dose Protein (Standardized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Standardized) | Arm Label: Standard protein supplementation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard Protein Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Individualized); Assigned to Arm(s): High Dose Protein (Individualized) | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Standardized); Assigned to Arm(s): High Dose Protein (Standardized) | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard Protein Supplementation; Assigned to Arm(s): Standard protein supplementation
D: Arm Label: Intervention group; Type: OTHER; Interventions: Dietary Supplement: Addition of human milk fortifiers according to human milk analysis | Intervention Type: DIETARY_SUPPLEMENT; Name: Addition of human milk fortifiers according to human milk analysis; Assigned to Arm(s): Intervention group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The prevention of postnatal growth failure in very low birth weight (VLBW) preterm infants is of utmost importance. Standard fortification is the most commonly used supplementation practice but it does not consider the native variability of human milk. Data on efficacy and safety of prolonged target fortification are scarce. The investigators performed a prospective interventional study in VLBW preterm infants, exclusively fed with human milk, to test efficacy and metabolic safety of target fortification in these preterm infants.


Options:
A: Arm Label: Human Milk Cream Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Human Milk Cream | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Human Milk Cream; Assigned to Arm(s): Human Milk Cream Group
B: Arm Label: Intervention group; Type: OTHER; Interventions: Dietary Supplement: Addition of human milk fortifiers according to human milk analysis | Intervention Type: DIETARY_SUPPLEMENT; Name: Addition of human milk fortifiers according to human milk analysis; Assigned to Arm(s): Intervention group
C: Arm Label: High Dose Protein (Individualized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Individualized) | Arm Label: High Dose Protein (Standardized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Standardized) | Arm Label: Standard protein supplementation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard Protein Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Individualized); Assigned to Arm(s): High Dose Protein (Individualized) | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Standardized); Assigned to Arm(s): High Dose Protein (Standardized) | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard Protein Supplementation; Assigned to Arm(s): Standard protein supplementation
D: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Arm Label: Routine fortification of breast milk; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Routine fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Routine fortification of breast milk; Assigned to Arm(s): Routine fortification of breast milk

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pessary in Singleton Gestations With Short Cervix Without Prior Preterm Birth
Brief Summary: Spontaneous preterm birth (SPTB) remains the number one cause of perinatal mortality in many countries, including the United States. In singleton gestations a short cervical length (CL) on transvaginal ultrasound (TVU) has been shown to be a good predictor of SPTB.

The cervical pessary is a silicone device that has been used to prevent SPTB. The efficacy of cervical pessary has been assessed in several populations including singletons with short CL, unselected twins, twins with a short CL, and triplet pregnancies. Several randomized clinical trials (RCTs) have been published, and several are ongoing. However, no consensus on the use of cervical pessary in pregnancy or guidelines for management have been assessed.


Options:
A: Arm Label: Pessary; Type: EXPERIMENTAL; Interventions: Device: Bioteque cup pessary | Arm Label: No pessary; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bioteque cup pessary; Assigned to Arm(s): Pessary
B: Arm Label: pessary; Type: EXPERIMENTAL; Interventions: Device: pessary | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DEVICE; Name: pessary; Assigned to Arm(s): pessary
C: Arm Label: Vaginal micronized progesterone; Type: EXPERIMENTAL; Interventions: Drug: Vaginal micronized progesterone | Arm Label: Cervical pessary; Type: ACTIVE_COMPARATOR; Interventions: Device: Cervical pessary | Intervention Type: DRUG; Name: Vaginal micronized progesterone; Assigned to Arm(s): Vaginal micronized progesterone | Intervention Type: DEVICE; Name: Cervical pessary; Assigned to Arm(s): Cervical pessary
D: Arm Label: Cervical Pessary; Type: EXPERIMENTAL; Interventions: Device: Cervical pessary | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cervical pessary; Assigned to Arm(s): Cervical Pessary

Answer: D